Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,475 across all filing types
Latest filing 2018-07-31 Remuneration Information
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Remuneration Committee - Terms of Reference
Remuneration Information Classification · 95% confidence The document is titled 'Remuneration Committee - Terms of Reference' and details the structure, duties, powers, and procedures of the Remuneration Committee of the company. It focuses on governance aspects related to executive and director compensation policies and committee operations. There is no financial data, earnings information, or report publication mentioned. The content aligns with remuneration information about top executives and directors rather than a full report or announcement. Therefore, the document fits the Remuneration Information category (DEF 14A). The document length (6672 characters) supports it being a full terms of reference document rather than a brief announcement.
2018-07-31 English
Audit Committee - Terms of Reference
Governance Information Classification · 95% confidence The document is titled 'Audit Committee - Terms of Reference' and details the composition, duties, powers, meetings, and authority of the Audit Committee of Ascletis Pharma Inc. It outlines governance and oversight responsibilities related to financial reporting, risk management, internal controls, and the relationship with external auditors. There are no actual financial statements, audit results, or financial performance data included. The document is a governance framework document rather than an audit report or annual report. It does not announce or attach any report but rather sets out the committee's terms of reference. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2018-07-31 English
List of Directors and their Role and Function
Board/Management Information Classification · 100% confidence The document lists the members of the board of directors and their roles and functions, including committee memberships. It does not contain financial data, earnings, or detailed management discussion. It is an announcement related to the company's board structure and composition. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on board members and committees, confirming it is not a full report or other type of filing.
2018-07-31 English
AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
Governance Information Classification · 100% confidence The document is titled 'AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION' of Ascletis Pharma Inc. It contains detailed company constitutional documents including the company's objects, share capital, board of directors, general meetings, voting rights, and other governance-related provisions. The content is legal and governance in nature, focusing on the internal rules and structure of the company rather than financial performance or announcements. There is no indication of financial statements, audit reports, earnings, or meeting results. The document is lengthy (15,000 characters) and is clearly the full text of the company's constitutional documents. Therefore, the appropriate classification is Governance Information (CGR).
2018-07-31 English
ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS
Share Issue/Capital Change Classification · 90% confidence The document is an announcement of IPO allotment results for Ascletis Pharma Inc. It provides links to various PDF files containing the specific results of share applications (White/Yellow forms, CCASS instructions). Since this document serves as a notification and index for the release of the allotment results rather than the full financial report or a specific regulatory filing category like 'SHA' (which usually refers to capital changes for existing listed entities), it is best classified as a Regulatory Filing (RNS) as it pertains to the administrative process of an IPO.
2018-07-31 English
Land Parcel No. G11207-1, Pingshan New Area, Longgang, Shenzhen City Approval as executing entity of Urban Renewal Project
Regulatory Filings Classification · 95% confidence The document is an announcement from World Houseware (Holdings) Limited regarding the approval of an entity as the executing entity of an Urban Renewal Project. It references previous announcements and a circular related to substantial disposal and acquisition but does not contain financial statements, detailed financial data, or comprehensive report content. The document is relatively short (1813 characters) and serves as an update or announcement rather than a full report. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a regulatory certification or officer attestation. It is also not a voting result, director dealing, or capital change notice. The content is best classified as a general regulatory announcement about project approval, which fits the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2018-07-20 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.